Main Sector of relevance\IRC classification 10. Other Industrial Manufacturing Technologies
10.11 FLUDARABEL – pharmaceutical substance and medical drug
Developers’ contact information
State Scientific Institution “The Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus”
5, bldg. 2, Kuprevich Str., 220141 Minsk
Summary
FLUDARABEL is one of the most effective and perspective medical drugs for treatment of chronic B-cell lymphocytic leukaemia
Description
The original technology of chemosynthesis of the substance is protected by patent for invention of the Republic of Belarus No. 9975
Technology type
Technical advantages and economic benefits
FLUDARABEL is one of the most effective and perspective medical drugs for treatment of chronic B-cell lymphocytic leukaemia. The original and extremely effective technology makes it possible to obtain a substance of pharmacopeial purity (more than 99.6%) with high yield and freeze dried pharmaceutical form containing 0.5g of active substance. The developed technology allows reducing the drug price 1.5-fold in comparison to the analogue foreign drugs. FLUDARABEL is not produced on the territory of CIS countries.
Technology differentiation and uniqueness
The original high-technology synthesis scheme.
Context in which technology was identified
International Specialized Exhibition “Chemistry. Oil and Gas” 2006, 2008; National exhibition of the Republic of Belarus in the Bolivarian Republic of Venezuela “Expo Feria “BELARUS-2007”
Technological keywords
Anticancer drug, chronic lymphocytic leukaemia.
Development Stage
Intellectual property rights
Range of applications
—
Classifier Used at the EU Innovation Relay Centres
Preferable Regions
Practical experience
Introduction of the technology in production.
Environmental impact
None
Type of collaboration sought
Terms and restrictions
Terms of the license contract
Available technical assistance